GenPharmTox BioTech AG

GenPharmTox BioTech AG has developed a proprietary technology-platform for the analysis of drugs and chemicals in metabolism and toxicology.
First Class Service in ADME-Tox: Toxicity Testing; Metabolism Assays; Genetically Engineered V79 cells expressing individual CYPs from man, mouse, rat, and fish

Activity:

- Contract Research
- Research & Development

Product / Technology type(s) covered:

- Enzymes
- NCE (new chemical entities)
- Pharmaceuticals / Therapeutics
- Technology

Therapeutic targets:

- Arthritis / Rheumato
- Cancer
- Cardiovascular
- Central nervous system
- Dermatology
- Infectious Diseases
- Neurology
- Stroke

Markets Covered

a. HeadQuarter: Germany

b. Continent(s) active: Europe , North America , Asia , Australia/New-Zealand , Far East , Near/Middle East , Africa , Central/South America

c. Countries active: Germany, UK, France, Netherlands, Belgium, Slovenia, Croatia, Spain, Italy

Corporate data:

Number of Employees: 23

Turnover:

Amount:	Year:	Currency:
1000000	2002	Euro

Year founded: 2000